JPH04295428A - Antiallergic agent - Google Patents
Antiallergic agentInfo
- Publication number
- JPH04295428A JPH04295428A JP8116991A JP8116991A JPH04295428A JP H04295428 A JPH04295428 A JP H04295428A JP 8116991 A JP8116991 A JP 8116991A JP 8116991 A JP8116991 A JP 8116991A JP H04295428 A JPH04295428 A JP H04295428A
- Authority
- JP
- Japan
- Prior art keywords
- hesperidin
- antiallergic agent
- antiallergic
- compound
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000043 antiallergic agent Substances 0.000 title claims abstract description 7
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims abstract description 10
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims abstract description 10
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims abstract description 10
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims abstract description 10
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims abstract description 10
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims abstract description 10
- 229940025878 hesperidin Drugs 0.000 claims abstract description 10
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract description 5
- 230000003266 anti-allergic effect Effects 0.000 abstract description 5
- 241000700159 Rattus Species 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- -1 poultices Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Abstract
Description
【０００１】0001
【産業上の利用分野】本発明は、ヘスペリジンを有効成
分とする抗アレルギー剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an antiallergic agent containing hesperidin as an active ingredient.
【０００２】0002
【従来の技術】ヘスペリジンはフラボノイドの一種であ
り、植物成分でもある。該化合物については種々の薬理
作用が知られているが、抗アレルギー作用はまだ知られ
ていない。[Prior Art] Hesperidin is a type of flavonoid and also a plant component. Various pharmacological actions are known for this compound, but anti-allergic action is not yet known.
【０００３】0003
【発明の構成】本発明は、ヘスペリジンを有効成分とす
る抗アレルギー剤及び抗炎症剤に関する。ヘスペリジン
は下記の化学構造式で示される化合物である。DESCRIPTION OF THE INVENTION The present invention relates to an antiallergic agent and an antiinflammatory agent containing hesperidin as an active ingredient. Hesperidin is a compound represented by the chemical structural formula below.
【０００４】0004
【化１】[Chemical formula 1]
【０００５】該化合物は、賦形剤、滑沢剤、安定化剤等
の添加剤と共に公知の製剤技術を用いて、錠剤、カプセ
ル剤、注射剤、軟膏剤、パツプ剤、リニメント剤、ロー
ション剤等の種々の剤型とすることができ、浴用剤とし
て投与してもよい。該化合物は通常経口、又は非経口投
与され、経口投与の場合には大人一人当たり通常２５〜
５００ｍｇ／日の投与量で抗アレルギー作用及び抗炎症
作用を充分に発揮することができ、又外用剤として投与
する場合には投与量は特に限定されず、適量を使用すれ
ばよい。[0005] The compound can be prepared into tablets, capsules, injections, ointments, poultices, liniments, and lotions using known formulation techniques together with additives such as excipients, lubricants, and stabilizers. It can be made into various dosage forms such as, and may be administered as a bath preparation. The compound is usually administered orally or parenterally, and in the case of oral administration, it is usually administered at a dose of 25 to 25% per adult.
Anti-allergic and anti-inflammatory effects can be sufficiently exhibited at a dosage of 500 mg/day, and when administered as an external preparation, the dosage is not particularly limited and an appropriate amount may be used.
【０００６】[0006]
【発明の効果】本発明にかかわるヘスペリジンは優れた
抗アレルギー作用及び抗炎症作用を有するものであり、
しかも安全性の上で問題となるようなものは見い出され
なかった。従って、該化合物は、抗アレルギー剤及び抗
炎症剤として優れたものである。以下、本発明を更に実
施例によって説明するが、本発明は以下の実施例によっ
て限定されるものではない。[Effects of the Invention] Hesperidin according to the present invention has excellent antiallergic and antiinflammatory effects,
Furthermore, no safety issues were found. Therefore, this compound is excellent as an antiallergic agent and an antiinflammatory agent. EXAMPLES Hereinafter, the present invention will be further explained with reference to examples, but the present invention is not limited to the following examples.
【実施例】ＩｎｔａｃｔラットにおけるＥＷＡラット血
清による４８時間ｈｏｍｏｌｏ−ｇｏｕｓ ＰＣＡ反
応に及ぼすヘスペリジンの影響を検討した。即ち、ラッ
トの背部皮内に生理食塩水で希釈した抗ＥＷＡラット血
清を０．０５ｍｌ／匹注射した。４８時間後、抗原（Ｅ
ＷＡ）を含むエバンスブルー生理食塩水溶液を０．５ｍ
ｌ尾静脈注射し、３０分後に放血致死させ皮膚青染部を
切り取り、含有色素量を測定した。試験化合物は試験開
始１時間前に経口投与した。対照には０．２％のカルボ
キシメチルセルロースナトリウム溶液のみを投与した。
結果は試験ラット数８匹からの〔平均±標準誤差〕とし
て表わした。結果を以下の表１に示した。EXAMPLE The effect of hesperidin on the 48-hour homolo-gous PCA reaction with EWA rat serum in intact rats was investigated. That is, 0.05 ml of anti-EWA rat serum diluted with physiological saline was injected intradermally into the backs of rats. After 48 hours, antigen (E
0.5 m of Evans blue saline solution containing
The animals were injected into the tail vein, and 30 minutes later, they were sacrificed by exsanguination, and the blue-stained skin was cut off to measure the amount of pigment contained. The test compound was orally administered 1 hour before the start of the test. Controls received only 0.2% sodium carboxymethylcellulose solution. Results were expressed as mean ± standard error from 8 rats tested. The results are shown in Table 1 below.
【０００７】[0007]
【表１】[Table 1]
【０００８】上表から明らかな如く、ヘスペリジンは４
８時間ｈｏｍｏｌｏｇｏｕｓ ＰＣＡラットの青染部
色素量を用量依存的に抑制し、０．１ｍＭ／ｋｇ投与群
には３６．８％の抑制率が認められた。As is clear from the above table, hesperidin has 4
The amount of blue dye in homologous PCA rats for 8 hours was suppressed in a dose-dependent manner, and an inhibition rate of 36.8% was observed in the 0.1 mM/kg administration group.
Claims (2)
ルギー剤。Claim 1: An anti-allergic agent containing hesperidin as an active ingredient.
剤。2. An anti-inflammatory agent containing hesperidin as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8116991A JPH04295428A (en) | 1991-03-22 | 1991-03-22 | Antiallergic agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8116991A JPH04295428A (en) | 1991-03-22 | 1991-03-22 | Antiallergic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH04295428A true JPH04295428A (en) | 1992-10-20 |
Family
ID=13738959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8116991A Pending JPH04295428A (en) | 1991-03-22 | 1991-03-22 | Antiallergic agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH04295428A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998016220A1 (en) * | 1996-10-14 | 1998-04-23 | Korea Institute Of Science And Technology | HESPERIDIN AND HESPERETIN AS 3-HYDROXY-3-METHYLGLUTARYL CoA(HMG-CoA) REDUCTASE INHIBITOR |
| JPH11100325A (en) * | 1997-07-31 | 1999-04-13 | Hayashibara Biochem Lab Inc | Composition |
| WO1999021549A1 (en) * | 1997-10-28 | 1999-05-06 | Korea Institute Of Science And Technology | Hesperidin and hesperetin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases |
| JP2003169631A (en) * | 2001-12-07 | 2003-06-17 | Snow Brand Milk Prod Co Ltd | Anti-allergic drink or food |
| US6602517B2 (en) * | 1999-04-30 | 2003-08-05 | Metagenics, Inc. | Dietary supplements for treating inflammation-related diseases |
| JP2005132792A (en) * | 2003-10-31 | 2005-05-26 | Univ Kinki | Antipruritic agent |
| JP2005132793A (en) * | 2003-10-31 | 2005-05-26 | Univ Kinki | Bleaching agent or dyspigmentation-improving agent |
| CN104825401A (en) * | 2015-04-22 | 2015-08-12 | 张永胜 | Dried orange peel extract freeze-dried powder injection and preparation method thereof |
| JP2019151568A (en) * | 2018-03-01 | 2019-09-12 | アサヒ飲料株式会社 | Enhancers of acid sphingomyelinase activity, compositions for enhancing acid sphingomyelinase activity and anti-allergic compositions |
| WO2020149373A1 (en) | 2019-01-16 | 2020-07-23 | 出光興産株式会社 | Plant growth regulating agent |
-
1991
- 1991-03-22 JP JP8116991A patent/JPH04295428A/en active Pending
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998016220A1 (en) * | 1996-10-14 | 1998-04-23 | Korea Institute Of Science And Technology | HESPERIDIN AND HESPERETIN AS 3-HYDROXY-3-METHYLGLUTARYL CoA(HMG-CoA) REDUCTASE INHIBITOR |
| JPH11100325A (en) * | 1997-07-31 | 1999-04-13 | Hayashibara Biochem Lab Inc | Composition |
| WO1999021549A1 (en) * | 1997-10-28 | 1999-05-06 | Korea Institute Of Science And Technology | Hesperidin and hesperetin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases |
| US6602517B2 (en) * | 1999-04-30 | 2003-08-05 | Metagenics, Inc. | Dietary supplements for treating inflammation-related diseases |
| JP2003169631A (en) * | 2001-12-07 | 2003-06-17 | Snow Brand Milk Prod Co Ltd | Anti-allergic drink or food |
| JP2005132792A (en) * | 2003-10-31 | 2005-05-26 | Univ Kinki | Antipruritic agent |
| JP2005132793A (en) * | 2003-10-31 | 2005-05-26 | Univ Kinki | Bleaching agent or dyspigmentation-improving agent |
| CN104825401A (en) * | 2015-04-22 | 2015-08-12 | 张永胜 | Dried orange peel extract freeze-dried powder injection and preparation method thereof |
| JP2019151568A (en) * | 2018-03-01 | 2019-09-12 | アサヒ飲料株式会社 | Enhancers of acid sphingomyelinase activity, compositions for enhancing acid sphingomyelinase activity and anti-allergic compositions |
| WO2020149373A1 (en) | 2019-01-16 | 2020-07-23 | 出光興産株式会社 | Plant growth regulating agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1045695B1 (en) | Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f 1? to treat peripheral vascular disease | |
| HU196124B (en) | Process for producing pharmaceutics comprising b under 12 vitamin and suitable for nasal dosage | |
| EP0214659A3 (en) | Peptide derivatives, process for the production thereof and pharmaceutical compositions containing same | |
| JPS58134031A (en) | Dihydrocyclosporin d for treating multiple screlosis | |
| JPH04295428A (en) | Antiallergic agent | |
| JP2526059B2 (en) | Anti-ulcer agent | |
| AU634189B2 (en) | Therapeutic agent for renal disorders | |
| US3519717A (en) | Novel method for lowering high blood pressure and compositions therefor | |
| JPH0137377B2 (en) | ||
| US3928609A (en) | Non-alcoholic theophylline product | |
| JPH0656669A (en) | Pterine derivative preparation having active oxygen-scavenging action | |
| JPH0425270B2 (en) | ||
| KR20010098583A (en) | Therapeutic agent for dermatitis | |
| US3193458A (en) | Method of lowering blood cholesterol level | |
| JPS6139287B2 (en) | ||
| US3993778A (en) | Anti-ulcerogenic pharmaceutical compositions containing a 2-amino-3,5-dibromo-benzylamine and method of use | |
| US4810707A (en) | Herpes simplex treatment | |
| JPH0144172B2 (en) | ||
| US3567828A (en) | Organic compounds | |
| JPS60208914A (en) | Preventive and remedy for hepatic disorder | |
| JPH04305527A (en) | Improver for oversensitiveness to cold | |
| JPS63267727A (en) | Drug comprising s-lactoylglutathione and/or salt thereof as active ingredient | |
| JPS5841820A (en) | Remedy for ulcer | |
| JPH03115222A (en) | Intravital lipoperoxide increase inhibiting agent | |
| US3855214A (en) | 2,3-dihydro-1h-pyridino{8 2,3-b{9 {8 1,4{9 -thiazine-2-one-4-oxide |